CD22 and B-cell neoplasm: In a clinical trial of a CD22 CAR-T cell therapy in children and young adults with CD22+ B-cell neoplasms, the change of the manufacturing protocol to CD4+ and CD8+ T cell selection improved manufacturing feasibility and reduced variability, however, this led to increased inflammatory toxicities and warranted dose de-escalation (35).